KT-333 is a first-in-class, potent, and selective heterobifunctional degrader of STAT3 that recruits the VHL E3 ligase for ubiquitin-proteasome-mediated degradation. It induces robust antitumor activity in preclinical models of ALK⁺ anaplastic large cell lymphoma (ALCL).